Navdeep Singh, Shivi Sondhi, Shammy Jindal, Vinay Pandit, Mahendra Singh Ashawat
Navdeep Singh*, Shivi Sondhi, Shammy Jindal, Vinay Pandit, Mahendra Singh Ashawat
Laureate Institute of Pharmacy Jawalamukhi, Kathog-177101, Distt. Kangra, Himachal Pradesh.
Volume - 10,
Issue - 4,
Year - 2020
Psoriasis is one of the major chronic disease which causes inflammation to the skin and also it is found to be an auto-immune disorder which affects 3% of the population globally. It can be characterized by evaluating the sign and symptoms and level of disease severity. The chances to develop other diseases in psoriasis are more common. We are focusing on the basic fundamentals of psoriasis as well as their treatment and management. Psoriasis is diagnosed on the basis of physical examination of the body including patient history, skin biopsy, Psoriasis Area Severity Index and Surface Area measurement of our body. The level of severity from mild, moderate and severe can be identified by these tests. However, the main fact that is important to deal with the patients is the prevalence and current scenario of psoriasis. Epidemiologically there are about 125million peoples affected around the world and 10million cases in India are observed annually. Basically many effective therapies are available to manage the symptoms of psoriasis which include topical, systemic, biological, natural herbs as well as phototherapy and combination therapy. Different routes are available for the application of these drugs and they include, topical, oral, intravenous, intramuscular, subcutaneous etc. All these treatments are applied for nourishing the life of patients and with the help of this treatment protocol we can cure and manage the disease.
Cite this article:
Navdeep Singh, Shivi Sondhi, Shammy Jindal, Vinay Pandit, Mahendra Singh Ashawat. Treatment and Management for patients with mild to severe Psoriasis: A Review. Asian J. Pharm. Res. 2020; 10(4):286-292. doi: 10.5958/2231-5691.2020.00049.0
Navdeep Singh, Shivi Sondhi, Shammy Jindal, Vinay Pandit, Mahendra Singh Ashawat. Treatment and Management for patients with mild to severe Psoriasis: A Review. Asian J. Pharm. Res. 2020; 10(4):286-292. doi: 10.5958/2231-5691.2020.00049.0 Available on: https://asianjpr.com/AbstractView.aspx?PID=2020-10-4-7
1. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES2003-2004.J Am Acad Dermatol. 2009; 60:218-224.
2. Menter A, Gottlieb A, Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2008; 58(5): 826–50.
3. Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol. 2010; 76:595–601.
4. Mohammed Nazeer, Surya Ravindran, Geethu Gangadharan and Sebastian Criton. A Survey of Treatment Practices in Management of Psoriasis Patients among Dermatologists of Kerela. Indian Dermatol Online J.2019, 10(4): 437-440.
5. Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmunity reviews. 2014 May 31; 13(4): 490-5.
6. Krueger G, Ellis CN. Psoriasis- recent advances in understanding its pathogenesis and treatment. Journal of the American Academy of Dermatology. 2005 Jul 31; 53(1): S94-100.
7. Bowcock AM and Krueger JG. Getting under the skin: The immunogenetics of psoriasis. Nature 2005; 5: 699-711.
8. Nickoloff BJ and Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities J. Clin Invest 2004; 113: 1664-75.
9. Junko Takeshita. Psoriasis and comorbid diseases epidemiology. Jamacad Dermatol volume76, number (3), March 2017: 377-84.
10. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015; 41: 545-568.
11. Alberti KG, Zimmet P and Shaw J. The metabolic syndrome: A new worldwide definition. IDF Epidemiology Task Force Consensus Group Lancet. 2005; 366: 1059-62.
12. Ogdie A, Schwartzman S, Eder L, Maharaj AB, Zisman D and Raychaudhuri SP. Comprehensive treatment of psoriatic arthritis: managing. Comorbidities and extraarticular manifestations. J Rheumatol. 2014; 41: 2315-22.
13. Voiculescu VM, Lupu M, Papagheorghe L, Giurcaneanu C and Micu E. Psoriasis and Metabolic Syndrome - scientific evidence and therapeutic implications. J Med Life. 2014; (7): 468-71.
14. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS and Colucci WS. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004; 109:1594-602.
15. Convit J. Investigation of the incidence of psoriasis amongst Latin-American Indians. In: Proceedings of 13th Congress on Dermatology. Amsterdam: Excerpta Medica, 1962:196.
16. Burch PR, Rowell NR. Mode of inheritance in psoriasis. Arch Dermatol. 1981; 117:251–2.
17. Sanjay kumar Rout1*, Bankim Chandra Tripathy2 and Vikash Ranjan Kar3. Natural Green Alternatives to Psoriasis Treatment- A Review. Glob J Pharmaceut Sci. 2017; 4(1): 555631.
18. Yashuda T, Ishikawa E, Mori S. Psoriasis in the Japanese. In: Farbert EM, Cox AJ, eds. Psoriasis. Proceedings of the 1st International Symposium. Stanford CA: Stanford University Press. 1971:25–34.
19. Mease PJ, Armstrong AW. Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis. Drugs. 2014; 74:423-41.
20. Weigle N and McBaneS. Psoriasis. Am Fam Physician. 2013 May; 87 (9): 626–33.
21. Bjorneboe A, Smith AK, Bjorneboe GEA, Thune P, Drevon C. Effect of Dietary Supplementation with n-3 Fatty acids on Clinical Manifestations of Psoriasis. British Journal of Dermatology. 1988; 118:77-83.
22. Brown AC, Hairfield M, Richards DG, McMillin DL, Mein EA and Nelson CD. Medical Nutrition Therapy as a Potential Complementary Treatment for Psoriasis-Five Case Reports. Alternative Medicine Review. 2004; (9):297-307.
23. Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E and Nast A. Efficacy and Safety of Systemic Treatments for Moderate-to-Severe Psoriasis: Meta-analysis of Randomized Controlled Trials. British Journal of Dermatology. 2014; 170:274-303.
24. Dommasch Ed, Abuabara K, Shin DB, Nguyen J, Troxel AB and Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011; 64(6):1035-50.
25. Ekor M. The Growing use of Herbal Medicines: Issues Relating to Adverse Reactions and Challenges in Monitoring Safety. Frontiers in Pharmacology. 2013; (4):177.
26. Weischer M, Blum A, Eberhard F, Röcken M, Berneburg M. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol 2004; 84(5):370-4.
27. Cheryl J. Gustafson, Casey Watkins, Emily Hix and Steven R. Feldman. Combination Therapy in Psoriasis. Am J Clin Dermatol 2013: (14):9–25.